Therefore, we focused on the presence of s‐p53‐Abs and/or s‐NY‐ESO‐1‐Abs to examine the positive rate, clinicopathological significance, and prognostic impact on ESCC, gastric cancer, and HCC. This evidence concerns the gene TP53 and gastric cancer.